Results 41 to 50 of about 57,118 (288)

Advancing precision medicine in axial spondyloarthritis: insights from multi-omics approaches

open access: yesFrontiers in Medicine
Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease influenced by genetic, immune, metabolic, and environmental factors, significantly impacting patients’ quality of life.
Yuanpiao Ni   +8 more
doaj   +1 more source

Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces [PDF]

open access: yes, 2013
BACKGROUND: Hyperuricemia (HUA) is a potential risk factor for developing insulin resistance, hypertension, dyslipidemia and cardiovascular disease.
Guang-jin Zhu   +11 more
core   +1 more source

Perceptions About Asymptomatic Hyperuricemia and Views About Urate‐Lowering Therapy in People With Asymptomatic Hyperuricemia

open access: yesArthritis Care &Research, EarlyView.
Objective Asymptomatic hyperuricemia is a precursor of gout and is also associated with cardiovascular disease and chronic kidney disease. The aim of this study was to understand perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia. Methods Participants in a multinational study of
Nicola Dalbeth   +19 more
wiley   +1 more source

Risk Factors in the Incidence of Gouty Arthritis in Masohi Town, Central Maluku Regency in 2010 [PDF]

open access: yes, 2012
The gouty arthritis incidence rate in Masohi Townof Central Maluku Regency is 54 people based on the data from the general  hospital in Masohi. The aim of study was to find out the risk factor in the incidence of gouty arthritis in Masohi Town of ...
Amiruddin, R. (Ridwan)   +2 more
core   +1 more source

Response to allopurinol and febuxostat according to the fractional excretion of urate in men with gout

open access: yesArthritis Care &Research, Accepted Article.
Background Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of urate (FEUA) also modulates this response and relates to oxypurinol concentrations. We further evaluated its potential influence
Pascal Richette   +13 more
wiley   +1 more source

Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality. [PDF]

open access: yes, 2019
Objective:The interleukin-1 (IL-1) receptor antagonist anakinra is an effective, off-label option in acute gout flares, when conventional therapy options are narrowed.
Pedersen, Brian   +2 more
core  

Pharmacology and clinical drug candidates in redox medicine [PDF]

open access: yes, 2015
SIGNIFICANCE Oxidative stress is suggested to be a disease mechanism common to a wide range of disorders affecting human health. However, so far, the pharmacotherapeutic exploitation of this, for example, based on chemical scavenging of pro-oxidant ...
Casas, Ana I   +11 more
core   +3 more sources

ITM2B Truncation Promotes Migrasome Formation to Accelerate Renal Cell Carcinoma Growth

open access: yesAdvanced Science, EarlyView.
This study identifies truncated ITM2B as a regulator of migrasome formation in renal cell carcinoma (RCC) cells. The ITM2B truncation not only facilitates migrasome formation by recruiting TSPAN4, but also sorts active caspase‐7 into migrasomes. The internalization of active caspase‐7‐enriched migrasomes by macrophages stimulates IL‐6 secretion to ...
Qi‐tao Chen   +10 more
wiley   +1 more source

Exploration of the anti-hyperuricemia effect of TongFengTangSan (TFTS) by UPLC-Q-TOF/MS-based non-targeted metabonomics

open access: yesChinese Medicine, 2023
Background TongFengTangSan (TFTS) is a commonly used Tibetan prescription for gout treatment. Previously, TFTS (CF) was confirmed to have a significant uric acid-lowering effect.
Zhichao Huang   +6 more
doaj   +1 more source

Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Non‐severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies.
Lele Zhang   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy